First treatment recommended for infants with Wolman Disease
European Pharmaceutical Review
NOVEMBER 27, 2023
The National Institute for Health and Care Excellence (NICE) has recommended enzyme replacement therapy sebelipase alfa (Kanuma ® ▼) in final draft guidance. This ultra-rare metabolic disease occurs due to lysosomal acid lipase (LAL) enzyme deficiency. How does the enzyme replacement therapy work?
Let's personalize your content